全文获取类型
| 收费全文 | 142174篇 |
| 免费 | 10764篇 |
| 国内免费 | 4068篇 |
专业分类
| 耳鼻咽喉 | 1044篇 |
| 儿科学 | 2420篇 |
| 妇产科学 | 2246篇 |
| 基础医学 | 8268篇 |
| 口腔科学 | 3148篇 |
| 临床医学 | 16823篇 |
| 内科学 | 21529篇 |
| 皮肤病学 | 2403篇 |
| 神经病学 | 7018篇 |
| 特种医学 | 4494篇 |
| 外国民族医学 | 43篇 |
| 外科学 | 17601篇 |
| 综合类 | 20767篇 |
| 现状与发展 | 23篇 |
| 一般理论 | 2篇 |
| 预防医学 | 5804篇 |
| 眼科学 | 2108篇 |
| 药学 | 11329篇 |
| 86篇 | |
| 中国医学 | 11369篇 |
| 肿瘤学 | 18481篇 |
出版年
| 2024年 | 268篇 |
| 2023年 | 2420篇 |
| 2022年 | 4644篇 |
| 2021年 | 6352篇 |
| 2020年 | 6074篇 |
| 2019年 | 5436篇 |
| 2018年 | 5131篇 |
| 2017年 | 5419篇 |
| 2016年 | 5711篇 |
| 2015年 | 5518篇 |
| 2014年 | 10193篇 |
| 2013年 | 12553篇 |
| 2012年 | 8208篇 |
| 2011年 | 8829篇 |
| 2010年 | 7354篇 |
| 2009年 | 6776篇 |
| 2008年 | 6635篇 |
| 2007年 | 6981篇 |
| 2006年 | 6296篇 |
| 2005年 | 5599篇 |
| 2004年 | 4592篇 |
| 2003年 | 4092篇 |
| 2002年 | 3354篇 |
| 2001年 | 2928篇 |
| 2000年 | 2421篇 |
| 1999年 | 1887篇 |
| 1998年 | 1611篇 |
| 1997年 | 1379篇 |
| 1996年 | 1142篇 |
| 1995年 | 1023篇 |
| 1994年 | 816篇 |
| 1993年 | 642篇 |
| 1992年 | 570篇 |
| 1991年 | 501篇 |
| 1990年 | 440篇 |
| 1989年 | 382篇 |
| 1988年 | 383篇 |
| 1987年 | 342篇 |
| 1986年 | 275篇 |
| 1985年 | 329篇 |
| 1984年 | 270篇 |
| 1983年 | 203篇 |
| 1982年 | 204篇 |
| 1981年 | 208篇 |
| 1980年 | 168篇 |
| 1979年 | 144篇 |
| 1978年 | 83篇 |
| 1977年 | 56篇 |
| 1976年 | 56篇 |
| 1975年 | 43篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
71.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献72.
73.
《Journal of the American College of Surgeons》2020,230(4):363-370
- Download : Download high-res image (207KB)
- Download : Download full-size image
74.
75.
中西医结合治疗动眼神经麻痹疗效观察 总被引：2，自引：0，他引：2
李春林 《中国实用神经疾病杂志》2015,(10)
目的了解中西医结合法治疗动眼神经麻痹的临床疗效。方法对我院2012-03—2014-03收治的动眼神经麻痹患者进行抽样,择取74例患者随机分成2组,对照组予以基础性西医疗法,实验组在对照组治疗基础上予以中医疗法(包括针刺及服用中药正容汤等),观察2组患者的临床治疗效果。结果实验组总有效率(94.60%)明显高于对照组(64.86%),差异具有统计学意义(P0.05)。结论中西医结合法治疗动眼神经麻痹临床疗效确切,安全系数高,值得临床大力推广使用。 相似文献
76.
《Urologic oncology》2015,33(5):217-225
Although both surgery and radiation are potential curative options for men with clinically localized prostate cancer, a significant proportion of men with high-risk and locally advanced disease will demonstrate biochemical and potentially clinical progression of their disease. Neoadjuvant systemic therapy before radical prostatectomy (RP) is a logical strategy to improve treatment outcomes for men with clinically localized high-risk prostate cancer. Furthermore, delivery of chemotherapy and other systemic agents before RP affords an opportunity to explore the efficacy of these agents with pathologic end points.Neoadjuvant chemotherapy, primarily with docetaxel (with or without androgen deprivation therapy), has demonstrated feasibility and safety in men undergoing RP, but no study to date has established the efficacy of neoadjuvant chemotherapy or neoadjuvant chemohormonal therapies. Other novel agents, such as those targeting the vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, clusterin, and immunomodulatory therapeutics, are currently under investigation. 相似文献
77.
78.
79.
80.